NONOF - Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
2024-05-02 12:21:14 ET
Novo Nordisk A/S (NVO)
Q1 2024 Earnings Conference Call
May 2, 2024 07:00 a.m. ET
Company Participants
Lars Fruergaard Jørgensen - Chief Executive Officer
Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs
Doug Langa - Executive Vice President, Head of North America Operations
Martin Holst Lange - Executive Vice President, Head of Development
Karsten Munk Knudsen - Chief Financial Officer
Daniel Bohsen - Head of Investor Relations
Conference Call Participants
Michael Nedelcovych - TD Cowen
Richard Vosser - JPMorgan
Louise Chen - Cantor Fitzgerald
Evan Seigerman - BMO Capital Markets
Sachin Jain - Bank of America
Peter Verdult - Citi
Simon Baker - Redburn Atlantic
Florent Cespedes - Bernstein
Mark Purcell - Morgan Stanley
Harry Sephton - UBS
Richard Parkes - BNP Paribas Exxon
Michael Novod - Nordea
Presentation
Operator
Good day! And thank you for standing by. Welcome to the Q1, 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Daniel Bohsen, CVP, Investor Relations. Please go ahead, sir.
Daniel Bohsen
Thank you. Welcome to this Novo Nordisk earnings call for the first three months of 2024. My name is Daniel Muusmann Bohsen and I'm the Head of Investor Relations at Novo Nordisk. With me today I have CEO of Novo Nordisk, Lars Fruergaard Jørgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally Chief Financial Officer, Karsten Munk Knudsen. All speakers will be available for the Q&A session.
Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that this call is being webcasted live and a recording will be made available on our website as well. The call is scheduled to last one hour.
Please turn to the next slide. The presentation is structured as outlined on slide two. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified.
Please turn to the next slide. We need to advise you that this call will contain forward-looking statements. These are subject to risk and uncertainty that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the first three months of 2024 and the slides prepared for this presentation.
With that, over to you Lars for an update on our strategic aspirations.
Lars Fruergaard Jørgensen
Thank you, Daniel. Please turn to the next slide. In the first three months, we have delivered 24% sales growth and 30% operating profit growth. Furthermore, we have raised the outlook for the full year. I would like to start this call by going through the performance highlights across our strategic aspirations before handing over the word to my colleagues. ...
Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript